Immuno-oncology therapies require more than target binding data. They require functional proof that immune cells can recognize, activate, and eliminate tumor cells.
CliniSciences provides advanced tumor–immune co-culture systems that measure immune-mediated tumor killing in a controlled, reproducible, and translational in vitro environment.
Bridge Mechanism to Functional Evidence
Our platform allows you to evaluate:
- Immune cell activation
- Tumor cell lysis
- Cytotoxic potency
- Cytokine release
- Combination efficacy
- Immune escape modulation
All within a human-based assay system.
Platform Overview
Tumor Component
- Well-characterized cancer cell lines
- 3D spheroids for enhanced physiological relevance
- Optional patient-derived tumor cultures
Immune Component
- PBMCs
- T cells
- NK cells
- Monocyte/macrophage subsets
- Custom immune populations (project-based)
Functional Readouts
Tumor Killing Assessment
- Luminescence viability assays
- Live/Dead fluorescence imaging
- MTT
- Apoptosis assays (TUNEL, nucleosome ELISA)
- Time-dependent cytotoxicity profiling
Immune Activation Assessment
- Flow cytometry phenotyping
- Proliferation markers (Ki-67)
- Cytokine quantification (ELISA panels)
- Immune activation markers (project-defined panels)
Combination Strategy Testing
Evaluate:
- Checkpoint inhibitors + your asset
- Bispecific antibodies
- Immune activators + targeted therapy
- Dose optimization and synergy mapping
Generate clear combination ranking and functional differentiation data.
Applications
- Early immuno-oncology proof-of-concept
- Mechanism-of-action validation
- Candidate ranking
- IND-enabling data support
- Competitive benchmarking
- Partnering and investor-ready datasets
Why CliniSciences
- Human-based functional testing
- Flexible and customizable assay design
- Faster than in vivo tumor models
- Modular integration with molecular and protein analysis
- Designed to reduce translational risk
